Cipla and Qilu Pharmaceutical Forge US Licensing Pact for QL2107, a Pembrolizumab Biosimilar Targeting Blockbuster Keytruda®
Pharm'Up 
Invagen Pharmaceuticals Inc., a wholly owned subsidiary of Indian multinational pharmaceutical company Cipla Limited (BSE: 500087; NSE: CIPLA), has entered into an exclusive strategic licensing and supply collaboration with China-based Qilu Pharmaceutical Co., Ltd. for QL2107, an investigational biosimilar candidate to the oncology blockbuster Keytruda® (pembrolizumab), specifically designated for the United States market.
Defined Strategic Alliance & Operational Roles
The cross-border partnership establishes a clear division of operational responsibilities to accelerate the candidate through remaining clinical and regulatory milestones:
- Development, Registration & Supply: Qilu Pharmaceutical will lead all ongoing clinical trial phases, manage regulatory filings with the US Food and Drug Administration (USFDA), and oversee the long-term commercial-scale manufacturing and active supply chain for the finished biologic.
- US Market Commercialization: Cipla USA Inc. will steer commercial launch strategies, sales execution, managed care access, and nationwide distribution, capitalizing on its established commercial presence and hospital-channel reach across North America.
Addressing the High Burden of Immuno-Oncology Care
Keytruda® (pembrolizumab)—a programmed death receptor-1 (PD-1) blocking antibody—is widely utilized across numerous oncological indications, including advanced non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma, and head and neck cancers. Given its prominence as a foundational immunotherapy, bringing an accessible, high-quality biosimilar alternative to market aims to alleviate significant budgetary pressures on healthcare payers and substantially decrease direct out-of-pocket costs for cancer patients.
Executive Leadership Perspectives
- Achin Gupta, Managing Director & Global Chief Executive Officer, Cipla: Emphasized that the agreement solidifies Cipla’s confidence in the long-term commercial potential of biosimilars while accelerating the company’s broader agenda to build a specialized, high-barrier oncology portfolio across its core global markets.
- Marc Falkin, Chief Executive Officer, Cipla North America: Highlighted that the integration of QL2107 aligns with Cipla North America’s multi-year strategy to significantly scale its biologics and biosimilar offerings, stating that the company’s commercial infrastructure is well-positioned to execute an impactful launch upon receiving US regulatory approval.
- Hanchang Zhang, General Manager of Qilu Pharmaceutical: Noted that combining Qilu’s robust research, bioprocess development, and manufacturing engine with Cipla’s US commercialization capabilities creates an ideal platform to bring affordable pembrolizumab biosimilar options to American patients.
About the Author
